KBC Group NV increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 54.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report), with a ...

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Thursday, Clear Street initiated coverage on Protagonist Therapeutics (NASDAQ: NASDAQ:PTGX), currently valued at $2.4 billion, with a Buy rating and a price target of $63.00.

Goldstein highlights Enliven Therapeutics (ELVN), Protagonist (PTGX), and Delcath (DCTH) as top biotech picks. To watch more expert insights and analysis on the latest market action, check out ...